N-acetyl-D-mannosamine (ManNAc) for age-related decline in place learning in dogs
Five older Labrador Retrievers (93.60 ± 11.98 months) with low cognitive levels, living at a guide dog facility, received 2-month courses of 250 mg oral ManNAc and of glucose control in a crossover design with a 1-month washout. ManNAc significantly reduced place-learning error trials, especially in the first month, and three dogs improved in their active-resting cycle. Because the sample was 4 or 5 dogs, significance was set at 10%.
Record
| Design | crossover trial |
|---|---|
| Status | completed |
| Intervention | N-acetyl-D-mannosamine (ManNAc), oral capsule |
| Intervention class | drug |
| Comparator | Glucose capsule (control, equivalent calorie value) |
| Dose regimen | One capsule containing 250 mg ManNAc or glucose orally once a day for 2 months |
| Duration | 2-month courses of each treatment in a crossover design with a 1-month washout period |
| Dogs | 5 |
| Population note | 5 dogs with low cognitive levels (1 male, 4 females); statistical analyses on n=4 or 5 |
| Breed | Labrador Retriever |
| Age | 93.60 ± 11.98 months |
| Other | Retired or demonstration dogs living at the Japan Guide Dog Association facility, in good health on medical examination |
| Primary outcome | Number of error trials in a place-learning test; active-resting cycle (daytime/nighttime motor activity ratio) |
| Result (as reported) | ManNAc treatment significantly reduced the number of error trials in the place-learning test, especially in the first month of administration. Three ManNAc-treated dogs also showed improvement in the active-resting cycle. In conclusion, ManNAc treatment appears to alleviate age-related cognitive dysfunction. |
| Tags | cognition, mannac, place-learning, crossover, labrador-retriever |
Notes: Dogs were retired or demonstration dogs at the Japan Guide Dog Association facility, so setting is neither a laboratory colony nor client-owned and is left null. ManNAc is described by the authors as a therapeutic agent, so intervention_class is recorded as drug. Full-text quotes include the Markdown line breaks of the corpus file.
Sources and verbatim quotes
N-acetyl-D-mannosamine treatment alleviates age-related decline in place-learning ability in dogs. (2014) PMID 24430654 (results)
This study aimed to investigate the therapeutic effects of N-acetyl-D-mannosamine (ManNAc) on age-related cognitive dysfunction in dogs. ManNAc was administered to 5 dogs with low cognitive levels for 2 months, and the cognitive ability and active-resting cycle were periodically assessed for improvement.
ManNAc treatment significantly reduced the number of error trials in the place-learning test, especially in the first month of administration. Three ManNAc-treated dogs also showed improvement in the active-resting cycle. In conclusion, ManNAc treatment appears to alleviate age-related cognitive dysfunction.
N-acetyl-D-mannosamine treatment alleviates age-related decline in place-learning ability in dogs. (2014) PMID 24430654 (design)
The subjects were 5 Labrador Retrievers (1 male and 4 females, aged 93.60 ± 11.98 months;
They were among the older dogs in the facility and, being retired or used only for demonstrations, were able to remain in the facility throughout the experiment.
All dogs underwent medical examination, including blood tests, and were found to be in good health.
The subjects of this study received 2-month courses of treatment with both ManNAc and glucose (control, an equivalent calorie value) in a crossover design with a 1-month washout period. One capsule containing 250 mg ManNAc or glucose was administered orally to each subject once a day for 2 months.
As the sample size was limited (n=4 or 5), the level of statistical significance was set at 10%.
Reproduce: canine_trial_search(trial_id="mannac-place-learning-crossover-2014") in dog-geroscience-mcp; dataset canine-trial-registry.